	US 11,884,939 B2
	Vaccinia virus mutants useful for cancer immunotherapy
Liang Deng, New York, NY (US); Stewart Shuman, New York, NY (US); Ning Yang, New York, NY (US); Taha Merghoub, New York, NY (US); and Jedd Wolchok, New York, NY (US)
Assigned to Memorial Sloan Kettering Cancer Center, New York, NY (US)
Filed by MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY (US)
Filed on Dec. 29, 2021, as Appl. No. 17/565,332.
Application 17/565,332 is a division of application No. 16/612,127, granted, now 11,242,509, previously published as PCT/US2018/032451, filed on May 11, 2018.
Claims priority of provisional application 62/505,713, filed on May 12, 2017.
Prior Publication US 2022/0186192 A1, Jun. 16, 2022
Int. Cl. C12N 15/86 (2006.01); C12N 7/00 (2006.01); C12N 15/63 (2006.01); C12N 15/863 (2006.01); A61K 39/285 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)

CPC C12N 7/00 (2013.01) [A61K 39/285 (2013.01); A61P 35/00 (2018.01); C12N 15/86 (2013.01); A61K 2039/525 (2013.01); A61K 2039/54 (2013.01); A61K 2039/55588 (2013.01); C12N 2710/24121 (2013.01); C12N 2710/24131 (2013.01); C12N 2710/24143 (2013.01)]

16 Claims

1. An engineered modified vaccinia Ankara (MVA) virus strain comprising a disruption of a C7L gene and a nucleotide sequence encoding human Fms-like tyrosine kinase 3 ligand (hFlt3L).